(6R)-6-[(1R,2S)-1,2-dihydroxypropyl]-2-(methylamino)-5,6,7,8-tetrahydro-3H-pteridin-4-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 蝶啶及其衍生物
• 英文名称: (6R)-6-[(1R,2S)-1,2-dihydroxypropyl]-2-(methylamino)-5,6,7,8-tetrahydro-3H-pteridin-4-one
• 化学式: C₁₀H₁₇N₅O₃
• 分子量: 255.27
• InChiKey: DLBFPLWERFVONK-BFHQHQDPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.5
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  118
• 氢给体数：
  6
• 氢受体数：
  5

文献信息

• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME<br/>[FR] COMPOSITIONS ET PROCÉDÉS POUR LE TRAITEMENT DU SYNDROME DU CÔLON IRRITABLE
  申请人：CELLIX BIO PRIVATE LTD

  公开号：WO2018029545A1

  公开（公告）日：2018-02-15

  The disclosures herein provide compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX, formula X, formula XI, formula XII, formula XIII, formula XIV and formula XV or its pharmaceutical acceptable salts, as well as polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These salts may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral administration, suppository, transdermal, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of irritable bowel syndrome (IBS), inflammatory bowel diseases or its associated complications.

  本公开提供化合物的公式I、公式II、公式III、公式IV、公式V、公式VI、公式VII、公式VIII、公式IX、公式X、公式XI、公式XII、公式XIII、公式XIV和公式XV，或其药用可接受盐，以及其多型、对映体、立体异构体、溶剂合物和水合物。这些盐可以制成药物组合物。药物组合物可以制成口服、栓剂、经皮、颊部、直肠、局部、经皮、经粘膜、静脉、全身、糖浆或注射用药物。这些组合物可用于治疗肠易激综合征（IBS）、炎症性肠病或其相关并发症。
• COMPOSITIONS AND METHODS FOR THE TREATMENT OF UREA CYCLE DISORDERS AND GOUT
  申请人：Alapati Mohan Murali

  公开号：US20160332950A1

  公开（公告）日：2016-11-17

  The disclosures herein provide compounds of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI and Formula VII or its pharmaceutical acceptable compositions and salts, as well as polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. The pharmaceutical compositions may be formulated for oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, nanoparticle, buccal administration or transdermal administration. Such compositions may be used to treatment of urea cycle disorders and gout or its associated complications.
• US9475747B1
  申请人：——

  公开号：US9475747B1

  公开（公告）日：2016-10-25
• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC SYNDROME AND LIPID DISORDERS<br/>[FR] COMPOSITIONS ET MÉTHODES POUR LE TRAITEMENT DU SYNDROME MÉTABOLIQUE ET DE TROUBLES LIPIDIQUES
  申请人：KANDULA MAHESH

  公开号：WO2014091465A2

  公开（公告）日：2014-06-19

  The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of metabolic syndrome and lipid disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of diabetes, hypertriglyceridemia, dyslipidemia, obesity and atherosclerosis.
• [EN] FATTY ACID CONJUGATES AND THEIR USES<br/>[FR] CONJUGUÉS D'ACIDES GRAS ET LEURS UTILISATIONS
  申请人：KANDULA MAHESH

  公开号：WO2014106805A2

  公开（公告）日：2014-07-10

  The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II; and methods for treating or preventing metabolic syndrome, cancer, a metabolic disease, a neurodegenerative disease and insulin resistance and diabetes may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of diabetes mellitus, obesity, lipid disorders, neuropathic pain, hypertriglyceridemia, hyperglycemia, hyperinsulinemia, metabolic syndrome, cancer, metabolic disease, neurodegenerative diseases and insulin resistance.